European Medicines Agency recommends authorisation of a third vaccine for influenza pandemic (H1N1) 2009

02 October 2009

The European Medicines Agency (EMEA) has recommended to the European Commission that a third influenza pandemic vaccine, Celvapan, be granted a marketing authorisation. This follows a decision by the Commission to grant authorisations for Focetria and Pandemrix. It is intended that both Celvapan and Pandemrix, will be available for use in Ireland.

Download EMEA Press Release

For more information on pandemic medication please go to the Pandemic Medication Webpage